<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155725</url>
  </required_header>
  <id_info>
    <org_study_id>FIDEL</org_study_id>
    <secondary_id>2013-002484-26</secondary_id>
    <nct_id>NCT02155725</nct_id>
  </id_info>
  <brief_title>Fibrinogen in Haemorrhage of Delivery</brief_title>
  <acronym>FIDEL</acronym>
  <official_title>Study on the Efficacy and Safety of a Therapeutic Strategy of PPH Comparing Early Administration of Human Fibrinogen vs Placebo in Patients Treated With IV Prostaglandins Following Vaginal Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the benefits of a therapeutic strategy that associates&#xD;
      an early administration of human fibrinogen concentrate in the management of PPH on the&#xD;
      reduction of bleeding after the initiation of prostaglandins intravenous infusion, following&#xD;
      vaginal delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, double-blind,multicenter, placebo-controlled study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 10, 2014</start_date>
  <completion_date type="Actual">August 6, 2018</completion_date>
  <primary_completion_date type="Actual">August 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure Rate of PPH Management</measure>
    <time_frame>Evaluation of the two criteria that form the primary endpoint within the 48 h following the administration</time_frame>
    <description>The primary efficacy variable is a binary (Failure versus Success) composite endpoint.&#xD;
Failure is defined when a patient:&#xD;
loses at least 4 g/dL of Hb compared to the reference Hb level , AND/OR&#xD;
requires the transfusion of at least 2 units of packed RBCs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With at Least Administration of 2 Units of RBCs</measure>
    <time_frame>from H0 to Day 2</time_frame>
    <description>Considering failure as the fact of requiring at least 2 units of RBCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Loss of at Least 4 g/dL of Hb</measure>
    <time_frame>From reference value to Day 2</time_frame>
    <description>Considering failure as the fact of having lost at least 4 g/dL of Hb.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Post-Partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Human Fibrinogen concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vials (200ml) / 3g intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 vials (200ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Fibrinogen concentrate</intervention_name>
    <description>Injection as soon as possible and within 30 min following the start of prostaglandin infusion</description>
    <arm_group_label>Human Fibrinogen concentrate</arm_group_label>
    <other_name>Clottafact, LFB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>As soon as possible and within 30 min following the start of prostaglandin infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
          -  Vaginal delivery&#xD;
&#xD;
          -  PPH requiring IV administration of prostaglandins&#xD;
&#xD;
          -  At least one available result of Hb level during the third trimester of pregnancy&#xD;
&#xD;
          -  18-year-old female patients and older&#xD;
&#xD;
          -  Covered by healthcare insurance in accordance with local requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Caesarean section&#xD;
&#xD;
          -  Haemostatic intervention (as ligation, embolization or hysterectomy) already decided&#xD;
             at the time of inclusion&#xD;
&#xD;
          -  Known placenta praevia or accreta&#xD;
&#xD;
          -  Hb level &lt; 10g/dl during the third trimester of pregnancy&#xD;
&#xD;
          -  History of venous or arterial thromboembolic event&#xD;
&#xD;
          -  Known inherited bleeding or thrombotic disorders&#xD;
&#xD;
          -  Treatment with low-molecular-weight heparin (LMWH) within 24 hours prior to the&#xD;
             inclusion&#xD;
&#xD;
          -  Treatment with acetylsalicylic acid within 5 days prior to the inclusion&#xD;
&#xD;
          -  Treatment with vitamin K antagonists within 7 days prior to the inclusion&#xD;
&#xD;
          -  Administration of fibrinogen concentrate within 48 hours prior to the inclusion&#xD;
&#xD;
          -  Administration of FFP, platelets units or prohaemostatic drugs, tranexamic acid and&#xD;
             rFVIIa or prothrombin complex concentrates (PCC) within 48 hours prior to the&#xD;
             inclusion&#xD;
&#xD;
          -  Administration of RBCs within 3 months prior to the inclusion&#xD;
&#xD;
          -  Participation in another interventional clinical study within 30 days prior to the&#xD;
             inclusion&#xD;
&#xD;
          -  Previous inclusion/enrolment in the present clinical study&#xD;
&#xD;
          -  Known history of hypersensitivity or other severe reaction to any component of&#xD;
             Clottafact® or placebo&#xD;
&#xD;
          -  Minors, majors under guardianship, persons staying in health or social institutes and&#xD;
             people deprived of their freedom&#xD;
&#xD;
          -  Known drug or alcohol abuse&#xD;
&#xD;
          -  Patients whose use of concomitant medication may interfere with the interpretation of&#xD;
             data&#xD;
&#xD;
          -  Any other current significant medical condition that might interfere with treatment&#xD;
             evaluation according to the investigator's judgement&#xD;
&#xD;
          -  Patients who are unlikely to survive through the treatment period and evaluation&#xD;
&#xD;
          -  Patients transferred from another service&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Sophie DUCLOY-BOUTHORS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternité Jeanne de Flandre - 59037 LILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric MERCIER, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Antoine Béclère - 92140 CLAMART</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre MIGNON, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Cochin - 75014 PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyril HUISSOUD, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Croix Rousse - 69004 LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marie GROUIN</last_name>
    <role>Study Chair</role>
    <affiliation>Université de Rouen - 76100 ROUEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Félix Guyon</name>
      <address>
        <city>Saint Denis</city>
        <state>Réunion</state>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Réunion</name>
      <address>
        <city>Saint Pierre</city>
        <state>Réunion</state>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé d'Antony</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Fleyriat</name>
      <address>
        <city>Bourg en Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux de Chartres (Hôpital Pasteur)</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille, Maternité Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph / Pôle Parents - Enfants</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternité Régionale Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims, Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de l'Atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44819</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul de Viguier - Site Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Martinique</name>
      <address>
        <city>Fort de France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>June 8, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPH</keyword>
  <keyword>fibrinogen</keyword>
  <keyword>vaginal delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02155725/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02155725/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02155725/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 10 April 2014 and 20 June 2018, 448 patients from 30 sites signed an informed consent.</recruitment_details>
      <pre_assignment_details>During the pre-assigment period 11 patients withdrawn before treatment period. (1 treated with another IMP, 5 not treated, 2 no emergency consent signed, 1 no post inclusion consent signed, 2 refused to continue the study)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clottafact</title>
          <description>Human fibrinogen concentrate 3g intravenous use. 2 vials of 1,5 g/100mL, each vial of powder was reconstituted with 100 mL of sterile water for injection.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo intravenous use. 2 vials of 100 mL, each vial of powder was reconstituted with 100 mL of sterile water.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clottafact</title>
          <description>Human fibrinogen concentrate 3g intravenous use. 2 vials of 1,5 g/100mL, each vial of powder was reconstitued with 100 mL of sterile water for injection.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo intravenous use. 2 vials of 100 mL, eache vial of powder was reconttitued with 100 mL of sterile water for injection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="224"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="437"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="224"/>
                    <count group_id="B2" value="213"/>
                    <count group_id="B3" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="224"/>
                    <count group_id="B2" value="213"/>
                    <count group_id="B3" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="5.6"/>
                    <measurement group_id="B2" value="30.3" spread="5.4"/>
                    <measurement group_id="B3" value="30.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="224"/>
                    <count group_id="B2" value="213"/>
                    <count group_id="B3" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Failure Rate of PPH Management</title>
        <description>The primary efficacy variable is a binary (Failure versus Success) composite endpoint.&#xD;
Failure is defined when a patient:&#xD;
loses at least 4 g/dL of Hb compared to the reference Hb level , AND/OR&#xD;
requires the transfusion of at least 2 units of packed RBCs.</description>
        <time_frame>Evaluation of the two criteria that form the primary endpoint within the 48 h following the administration</time_frame>
        <population>Number of patients with failure</population>
        <group_list>
          <group group_id="O1">
            <title>Per Protocole (PP) Set Clottafact</title>
            <description>Patients with no missing data for the primary criterion.</description>
          </group>
          <group group_id="O2">
            <title>Per Protocole (PP) Set Placebo</title>
            <description>Patients with no missing data for the primary criterion.</description>
          </group>
          <group group_id="O3">
            <title>Intention To Treat (ITT) Set Clottafact</title>
            <description>All patients treated with Clottafact. (patients who received at least one infusion of Clottafact)</description>
          </group>
          <group group_id="O4">
            <title>Intention To Treat (ITT) Set Placebo</title>
            <description>All patients treated with Placebo. (patients who received at least one infusion of placebo)</description>
          </group>
          <group group_id="O5">
            <title>Full Analysis Set (FAS) Clottafact</title>
            <description>Patients treated with Clottafact of the ITT Set with no missing data for the primary criteria.</description>
          </group>
          <group group_id="O6">
            <title>Full Analysis Set (FAS) Placebo</title>
            <description>Patients treated with Placebo of the ITT Set with no missing data for the primary criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Failure Rate of PPH Management</title>
          <description>The primary efficacy variable is a binary (Failure versus Success) composite endpoint.&#xD;
Failure is defined when a patient:&#xD;
loses at least 4 g/dL of Hb compared to the reference Hb level , AND/OR&#xD;
requires the transfusion of at least 2 units of packed RBCs.</description>
          <population>Number of patients with failure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9563</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9889</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6633</ci_lower_limit>
            <ci_upper_limit>1.4744</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With at Least Administration of 2 Units of RBCs</title>
        <description>Considering failure as the fact of requiring at least 2 units of RBCs.</description>
        <time_frame>from H0 to Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FAS Set Clottafact</title>
            <description>Patients treated with Clottafact of the ITT Set with no missing data for the primary criteria.</description>
          </group>
          <group group_id="O2">
            <title>FAS Set Placebo</title>
            <description>Patients treated with Placebo of the ITT Set with no missing data for the primary criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With at Least Administration of 2 Units of RBCs</title>
          <description>Considering failure as the fact of requiring at least 2 units of RBCs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Failure on individual component of the primary endpoint defined as administration of 2 units of RBCs.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9786</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0064</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6321</ci_lower_limit>
            <ci_upper_limit>1.6022</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Loss of at Least 4 g/dL of Hb</title>
        <description>Considering failure as the fact of having lost at least 4 g/dL of Hb.</description>
        <time_frame>From reference value to Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FAS Set Clottafact</title>
            <description>Patients treated with Clottafact of the ITT Set with no missing data for the primary criteria.</description>
          </group>
          <group group_id="O2">
            <title>FAS Set Placebo</title>
            <description>Patients treated with Placebo of the ITT Set with no missing data for the primary criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Loss of at Least 4 g/dL of Hb</title>
          <description>Considering failure as the fact of having lost at least 4 g/dL of Hb.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Failure on individual component of the primary endpoint defined as a loss of at least 4 g/dL of Hb.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9474</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0169</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6177</ci_lower_limit>
            <ci_upper_limit>1.6741</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The safety was assessed by recording all AEs occurring during the study, from signature of the informed consent to last study visit (6 +/- 2 weeks after delivery).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clottafact</title>
          <description>Human fibrinogen concentrate 3g intravenous use. 2 vials of 1,5 g/100mL, each vial of powder was reconstitued with 100 mL of sterile water for injection.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo intravenous use. 2 vials of 100 mL, eache vial of powder was reconttitued with 100 mL of sterile water.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute fatty liver of pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Blood pressure ambulatory increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>HELLP syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Broad ligament haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Uterine haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Uterine necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="224"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Puerperal pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Uterine pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vulval oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director France</name_or_title>
      <organization>LFB Biomédicaments</organization>
      <phone>33 169827229</phone>
      <email>zitounis@lfb.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

